Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... from the National Institute of Standards and Technology ... demonstrated a new design for an atomic clock ... or a microcomb. , The microcomb clock, featured ... the new journal Optica ,* is the ... and its accurate conversion of optical frequencies to ...
(Date:7/22/2014)... July 22, 2014 CTD Holdings, Inc. ... pharmaceutical, medical device, cosmetics, and other markets, announced today ... a group of qualified private investors led by Novit ... , The transaction involved the signing of a ... shares of Common Stock at a price per share ...
(Date:7/22/2014)... NJ (PRWEB) July 22, 2014 ... precision, portable, and mechanical balances and scales, proudly ... balances has won Laboratory Equipment magazine’s 2014 “Readers' ... the second consecutive year the Explorer was voted ... The annual Readers’ Choice Awards celebrates “excellence in ...
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a ... affordable vaccines based on proprietary manufacturing technologies and ... been awarded a proof of concept contract by ... laboratory specifically the Edgewood Chemical Biological Center ("ECBC") ...
... Guacamole is a little prettier in October as your ... "Pink" Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the ... proceeds from October "PINK" sales to help fight for ... of Texas-Based Wholly,s support for National Breast Cancer Awareness ...
... ... ... October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core ... iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment ...
Cached Biology Technology:Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy 2Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2
(Date:7/23/2014)... fatty acids and energy to infants and children ... that soybean-based emulsions could compromise immune functions and ... lipid emulsions based on triglyceride oil, fish oil, ... this concern. , However, researchers at Rutgers and ... according to a review published today in the ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... BEDFORD, Mass., July 22, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its second quarter ... quarter of 2014 was $6.8 million, an increase of 53% ... Operating income before patent related income in the second quarter ... the second quarter of 2013. The increase in revenue and ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... be taken during radiation therapy treatments because they ... normal prostate cell lines, leading to normal tissue ... issue of the International Journal of Radiation ... Society for Radiation Oncology (ASTRO). Many prostate cancer ...
... The Society for Nutrition Education (SNE) has ... American Society for Nutrition (ASN) to publish a ... American Society for Nutrition, and Society for Nutrition ... Adults," focusing on access to safe and adequate ...
... This release is available in Spanish . ... found in South America that can cause terrible, Ebola-like ... Now, Howard Hughes Medical Institute (HHMI) researchers ... hemorrhagic fever virus latches onto and infects human cells, ...
Cached Biology News:Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: